The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. · 2020
Read The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. by Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7292831.txt.
Description
Tang and co-authors review how liver cancer cells learn to resist sorafenib, a standard drug for advanced disease. Their review appeared in Signal Transduction and Targeted Therapy. Sorafenib blocks several enzymes at once, promoting cancer cell death, choking tumor blood supply, and slowing growth. It is an effective first-line therapy for late-stage hepatocellular carcinoma, yet resistance keeps developing.
Recent studies point to four sources of resistance: epigenetic changes that reprogram genes, transport processes that move the drug, shifts in how cells die, and the tumor microenvironment around the cancer. The authors summarize the principles behind each route and outline strategies intended to delay or reverse resistance and improve outcomes for patients whose tumors no longer respond.
Catalog record
| CREATOR | Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |